A Randomized, Double-Blind, Placebo-Controlled Subjective Study to Assess the Efficacy of APD125 in Patients With Primary Insomnia Characterized by Difficulty Maintaining Sleep
Phase of Trial: Phase II
Latest Information Update: 29 Dec 2008
At a glance
- Drugs Nelotanserin (Primary)
- Indications Insomnia
- Focus Therapeutic Use
- Sponsors Arena Pharmaceuticals
- 09 Dec 2008 Preliminary results announced by Aren Pharmaceuticals, indicating that the trial's primary and secondary endpoints have not been met. A full analysis is yet to be completed.
- 01 May 2008 Integrated NCT00664664
- 01 May 2008 The expected completion date for this trial is now 1 Oct 2008.